search
Back to results

CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease

Primary Purpose

Arterial Occlusive Diseases

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Clopidogrel
Sponsored by
Sanofi
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arterial Occlusive Diseases

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: A patient is eligible for inclusion in the study 2-4 days after surgery if all the following criteria are fulfilled: Informed consent obtained; Chronic background treatment with daily ASA, whatever the dose, started at least 4 weeks before surgery. A window of a few days without ASA before surgery is acceptable, according to local practice. Post-randomization use of ASA must be between 75 and 100 mg/day. Unilateral below knee bypass graft (i.e. the distal anastomosis is below the level of the knee joint) for atherosclerotic PAD within the previous 4 days; Demonstration of initial patency of the index graft by an objective measurement (e.g. intra-operative Doppler scanning, flow measurement, angiography, Duplex scanning) during bypass surgery, or between surgery and the time of randomization; No clinical evidence of graft occlusion at time of randomization. Exclusion criteria : PAD medical/surgical history Onset of PAD symptoms before the age of 40 years Non-atherosclerotic vascular disease (e.g. Buerger's disease, popliteal entrapment syndrome) Patient receiving aorto-bifemoral, iliac-femoral or crossover (femoral-femoral) grafts, or undergoing peripheral transcutaneous angioplasty (PTA), with or without stenting, during the same surgery. Medical history related to bleeding risk Current active bleeding at surgical site Withdrawal of an epidural catheter less than 12 hours before randomization Current active bleeding or increased risk of bleeding, such as severe hepatic insufficiency, proliferative diabetic retinopathy, peptic ulceration, bleeding diathesis or coagulopathy Peptic ulceration within 12 months of randomization Previous or current intracranial hemorrhage or hemorrhagic stroke, or any previous stroke for which the diagnosis of hemorrhagic stroke cannot be excluded Any history of severe spontaneous bleeding such as gastrointestinal bleeding, gross hematuria, intraocular bleeding Other medical conditions Previous disabling stroke (severe cerebral deficit such that the patient is bedridden or demented) NYHA Class IV heart failure Uncontrolled hypertension: Systolic Blood Pressure (SBP) > 180 mm Hg, or Diastolic Blood Pressure (DBP) > 100 mm Hg

Sites / Locations

  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis
  • Sanofi-Aventis

Outcomes

Primary Outcome Measures

1st occurrence over the duration of follow-up of : index bypass graft occlusion based on imaging procedure, or graft replacement or endovascular intervention, or amputation above the ankle of the affected limb or death

Secondary Outcome Measures

1st occurrence of any component of following cluster of events : index bypass graft occlusion,any revascularization procedure or amputation. Change in ABPI.

Full Information

First Posted
September 9, 2005
Last Updated
January 10, 2011
Sponsor
Sanofi
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00174759
Brief Title
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
Official Title
A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2011
Overall Recruitment Status
Completed
Study Start Date
September 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi
Collaborators
Bristol-Myers Squibb

4. Oversight

5. Study Description

Brief Summary
Primary objective: To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100 mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in patients receiving a below knee bypass graft for the treatment of PAD. Secondary objectives: Comparison, between the two treatment groups, of : Primary patency, Assisted primary patency, Cardiovascular death / myocardial infarction / stroke / any amputation above the ankle. Ankle Brachial Pressure Index (ABPI) changes from baseline

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Occlusive Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1460 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Clopidogrel
Primary Outcome Measure Information:
Title
1st occurrence over the duration of follow-up of : index bypass graft occlusion based on imaging procedure, or graft replacement or endovascular intervention, or amputation above the ankle of the affected limb or death
Secondary Outcome Measure Information:
Title
1st occurrence of any component of following cluster of events : index bypass graft occlusion,any revascularization procedure or amputation. Change in ABPI.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A patient is eligible for inclusion in the study 2-4 days after surgery if all the following criteria are fulfilled: Informed consent obtained; Chronic background treatment with daily ASA, whatever the dose, started at least 4 weeks before surgery. A window of a few days without ASA before surgery is acceptable, according to local practice. Post-randomization use of ASA must be between 75 and 100 mg/day. Unilateral below knee bypass graft (i.e. the distal anastomosis is below the level of the knee joint) for atherosclerotic PAD within the previous 4 days; Demonstration of initial patency of the index graft by an objective measurement (e.g. intra-operative Doppler scanning, flow measurement, angiography, Duplex scanning) during bypass surgery, or between surgery and the time of randomization; No clinical evidence of graft occlusion at time of randomization. Exclusion criteria : PAD medical/surgical history Onset of PAD symptoms before the age of 40 years Non-atherosclerotic vascular disease (e.g. Buerger's disease, popliteal entrapment syndrome) Patient receiving aorto-bifemoral, iliac-femoral or crossover (femoral-femoral) grafts, or undergoing peripheral transcutaneous angioplasty (PTA), with or without stenting, during the same surgery. Medical history related to bleeding risk Current active bleeding at surgical site Withdrawal of an epidural catheter less than 12 hours before randomization Current active bleeding or increased risk of bleeding, such as severe hepatic insufficiency, proliferative diabetic retinopathy, peptic ulceration, bleeding diathesis or coagulopathy Peptic ulceration within 12 months of randomization Previous or current intracranial hemorrhage or hemorrhagic stroke, or any previous stroke for which the diagnosis of hemorrhagic stroke cannot be excluded Any history of severe spontaneous bleeding such as gastrointestinal bleeding, gross hematuria, intraocular bleeding Other medical conditions Previous disabling stroke (severe cerebral deficit such that the patient is bedridden or demented) NYHA Class IV heart failure Uncontrolled hypertension: Systolic Blood Pressure (SBP) > 180 mm Hg, or Diastolic Blood Pressure (DBP) > 100 mm Hg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luc Sagnard
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-Aventis
City
North Ryde
Country
Australia
Facility Name
Sanofi-Aventis
City
Vienna
Country
Austria
Facility Name
Sanofi-Aventis
City
Brussels
Country
Belgium
Facility Name
Sanofi-Aventis
City
Helsinki
Country
Finland
Facility Name
Sanofi-Aventis
City
Paris
Country
France
Facility Name
Sanofi-Aventis
City
Berlin
Country
Germany
Facility Name
Sanofi-Aventis
City
Budapest
Country
Hungary
Facility Name
Sanofi-Aventis
City
Milan
Country
Italy
Facility Name
Sanofi-Aventis
City
Gouda
Country
Netherlands
Facility Name
Sanofi-Aventis
City
Warsaw
Country
Poland
Facility Name
Sanofi-Aventis
City
Barcelona
Country
Spain
Facility Name
Sanofi-Aventis
City
Stockholm
Country
Sweden
Facility Name
Sanofi-Aventis
City
Meyrin
Country
Switzerland
Facility Name
Sanofi-Aventis
City
Guildford
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
20678878
Citation
Belch JJ, Dormandy J; CASPAR Writing Committee; Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepantalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2. doi: 10.1016/j.jvs.2010.04.027. Epub 2010 Aug 1. Erratum In: J Vasc Surg. 2011 Feb;53(2):564. Biasi, B M [corrected to Biasi, G M].
Results Reference
derived

Learn more about this trial

CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease

We'll reach out to this number within 24 hrs